• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

探索锆-89在诊断放射性药物应用中的潜力:一项分析研究。

Exploring the Potential of Zirconium-89 in Diagnostic Radiopharmaceutical Applications: An Analytical Investigation.

作者信息

Mostafa Ahmed M A, Zakaly Hesham M H, Issa Shams A M, Uosif Mohamed A M, Alrowaili Ziyad A, Zhukovsky Michael V

机构信息

Physics Department, College of Science, Jouf University, Sakaka P.O. Box 2014, Saudi Arabia.

Institute of Physics and Technology, Ural Federal University, Ekaterinburg 620002, Russia.

出版信息

Biomedicines. 2023 Apr 13;11(4):1173. doi: 10.3390/biomedicines11041173.

DOI:10.3390/biomedicines11041173
PMID:37189792
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10135474/
Abstract

This study highlights the use of Zr-oxalate in diagnostic applications with the help of WinAct and IDAC2.1 software. It presents the biodistribution of the drug in various organs and tissues, including bone, blood, muscle, liver, lung, spleen, kidneys, inflammations, and tumors, and analyzes the maximum amount of nuclear transformation per Bq intake for each organ. The retention time of the maximum nuclear transformation and the absorbed doses of the drug in various organs and tissues are also examined. Data from clinical and laboratory studies on radiopharmaceuticals are used to estimate the coefficients of transition. The accumulation and excretion of the radiopharmaceutical in the organs is assumed to follow an exponential law. The coefficients of transition from the organs to the blood and vice versa are estimated using a combination of statistical programs and digitized data from the literature. WinAct and IDAC 2.1 software are used to calculate the distribution of the radiopharmaceutical in the human body and to estimate the absorbed doses in organs and tissues. The results of this study can provide valuable information for the biokinetic modeling of wide-spectrum diagnostic radiopharmaceuticals. The results show that Zr-oxalate has a high affinity for bones and a relatively low impact on healthy organs, making it helpful in targeting bone metastases. This study provides valuable information for further research on the development of this drug for potential clinical applications.

摘要

本研究强调了借助WinAct和IDAC2.1软件,草酸锆在诊断应用中的使用。它呈现了该药物在包括骨骼、血液、肌肉、肝脏、肺、脾脏、肾脏、炎症和肿瘤等各种器官和组织中的生物分布,并分析了每个器官每摄入1贝可的最大核转变量。还研究了最大核转变的保留时间以及该药物在各种器官和组织中的吸收剂量。来自放射性药物临床和实验室研究的数据用于估计转移系数。假定放射性药物在器官中的积累和排泄遵循指数规律。使用统计程序和文献中的数字化数据相结合的方法,估计从器官到血液以及从血液到器官的转移系数。WinAct和IDAC 2.1软件用于计算放射性药物在人体中的分布,并估计器官和组织中的吸收剂量。本研究结果可为广谱诊断放射性药物的生物动力学建模提供有价值的信息。结果表明,草酸锆对骨骼具有高亲和力,对健康器官的影响相对较低,这使其有助于靶向骨转移。本研究为进一步开发该药物用于潜在临床应用的研究提供了有价值的信息。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44b0/10135474/abb02470284f/biomedicines-11-01173-g002a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44b0/10135474/f716c8ffbcca/biomedicines-11-01173-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44b0/10135474/abb02470284f/biomedicines-11-01173-g002a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44b0/10135474/f716c8ffbcca/biomedicines-11-01173-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44b0/10135474/abb02470284f/biomedicines-11-01173-g002a.jpg

相似文献

1
Exploring the Potential of Zirconium-89 in Diagnostic Radiopharmaceutical Applications: An Analytical Investigation.探索锆-89在诊断放射性药物应用中的潜力:一项分析研究。
Biomedicines. 2023 Apr 13;11(4):1173. doi: 10.3390/biomedicines11041173.
2
Assessment of absorbed dose for Zr-89, Sm-153 and Lu-177 medical radioisotopes: IDAC-Dose2.1 and OLINDA experience.评估 Zr-89、Sm-153 和 Lu-177 医用放射性同位素的吸收剂量:IDAC-Dose2.1 和 OLINDA 经验。
Appl Radiat Isot. 2021 Oct;176:109841. doi: 10.1016/j.apradiso.2021.109841. Epub 2021 Jun 26.
3
Dosimetry Assessment of Injected 89Zr-Labeled Monoclonal Antibodies in Humans.人体注射 89Zr 标记单克隆抗体的剂量学评估。
Radiat Res. 2019 May;191(5):466-474. doi: 10.1667/RR15321.1. Epub 2019 Mar 21.
4
Influence of human biokinetics of strontium on internal ingestion dose of 90Sr and absorbed dose of 89Sr to organs and metastases.锶的人体生物动力学对90锶内摄入剂量及89锶对器官和转移灶吸收剂量的影响。
Radiat Environ Biophys. 2008 Apr;47(2):225-39. doi: 10.1007/s00411-007-0154-8. Epub 2008 Jan 19.
5
Calculation of radium-223 and actinium-225 α-emitter radiopharmaceuticals dose rates in treatment of metastatic castration-resistant prostate cancer.镭-223 和锕-225α 放射性药物在治疗转移性去势抵抗性前列腺癌中的剂量率计算。
J Cancer Res Ther. 2021 Apr-Jun;17(2):348-352. doi: 10.4103/jcrt.JCRT_892_18.
6
Preparation of Zirconium-89 Solutions for Radiopharmaceutical Purposes: Interrelation Between Formulation, Radiochemical Purity, Stability and Biodistribution.用于放射性药物目的的 89Zr 溶液的制备:制剂、放射化学纯度、稳定性和生物分布之间的关系。
Molecules. 2019 Apr 18;24(8):1534. doi: 10.3390/molecules24081534.
7
Comparative studies on the potential use of Lu-based radiopharmaceuticals for the palliative therapy of bone metastases.镥基放射性药物在缓解骨转移姑息治疗中应用的对比研究。
Int J Radiat Biol. 2020 Jun;96(6):779-789. doi: 10.1080/09553002.2020.1729441. Epub 2020 Mar 3.
8
More advantages in detecting bone and soft tissue metastases from prostate cancer using F-PSMA PET/CT.使用F-PSMA PET/CT检测前列腺癌骨和软组织转移方面有更多优势。
Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7.
9
Comparative study on application ofLu-labeled rituximab, tetulomab, cetuximab and huA33 monoclonal antibodies to targeted radionuclide therapy.Lu 标记利妥昔单抗、替妥珠单抗、西妥昔单抗和 HuA33 单克隆抗体在靶向放射性核素治疗中的应用比较研究。
Biomed Phys Eng Express. 2020 Dec 21;7(1). doi: 10.1088/2057-1976/abd307.
10
Technical note: A wearable radiation measurement system for collection of patient-specific time-activity data in radiopharmaceutical therapy: system design and Monte Carlo simulation results.技术说明:一种可穿戴辐射测量系统,用于收集放射性药物治疗中患者特定的时间-活性数据:系统设计和蒙特卡罗模拟结果。
Med Phys. 2021 Dec;48(12):8117-8126. doi: 10.1002/mp.15311. Epub 2021 Nov 23.

本文引用的文献

1
PET imaging of VEGFR and integrins in glioma tumor xenografts using Zr labelled heterodimeric peptide.使用锆标记的异二聚体肽对胶质瘤肿瘤异种移植中的血管内皮生长因子受体(VEGFR)和整合素进行正电子发射断层扫描(PET)成像。
Bioorg Med Chem. 2022 Apr 1;59:116677. doi: 10.1016/j.bmc.2022.116677. Epub 2022 Feb 22.
2
Assessment of absorbed dose for Zr-89, Sm-153 and Lu-177 medical radioisotopes: IDAC-Dose2.1 and OLINDA experience.评估 Zr-89、Sm-153 和 Lu-177 医用放射性同位素的吸收剂量:IDAC-Dose2.1 和 OLINDA 经验。
Appl Radiat Isot. 2021 Oct;176:109841. doi: 10.1016/j.apradiso.2021.109841. Epub 2021 Jun 26.
3
Comparative studies on the potential use of Lu-based radiopharmaceuticals for the palliative therapy of bone metastases.
镥基放射性药物在缓解骨转移姑息治疗中应用的对比研究。
Int J Radiat Biol. 2020 Jun;96(6):779-789. doi: 10.1080/09553002.2020.1729441. Epub 2020 Mar 3.
4
Dosimetry Assessment of Injected 89Zr-Labeled Monoclonal Antibodies in Humans.人体注射 89Zr 标记单克隆抗体的剂量学评估。
Radiat Res. 2019 May;191(5):466-474. doi: 10.1667/RR15321.1. Epub 2019 Mar 21.
5
Comparative biodistribution analysis across four different Zr-monoclonal antibody tracers-The first step towards an imaging warehouse.四种不同 Zr-单克隆抗体示踪剂的比较生物分布分析——迈向成像仓库的第一步。
Theranostics. 2018 Jul 30;8(16):4295-4304. doi: 10.7150/thno.26370. eCollection 2018.
6
Absorbed doses in humans from Re-Rituximab in the free form and bound to superparamagnetic iron oxide nanoparticles: Biodistribution study in mice.游离形式及与超顺磁性氧化铁纳米颗粒结合的利妥昔单抗在人体中的吸收剂量:小鼠体内生物分布研究
Appl Radiat Isot. 2018 Jan;131:96-102. doi: 10.1016/j.apradiso.2017.10.041. Epub 2017 Oct 23.
7
IDAC-Dose 2.1, an internal dosimetry program for diagnostic nuclear medicine based on the ICRP adult reference voxel phantoms.IDAC-Dose 2.1,一款基于国际辐射防护委员会(ICRP)成人参考体素模型的诊断核医学内照射剂量学程序。
EJNMMI Res. 2017 Nov 3;7(1):88. doi: 10.1186/s13550-017-0339-3.
8
Evaluation of [(89)Zr]-Oxalate as a PET Tracer in Inflammation, Tumor, and Rheumatoid Arthritis Models.[(89)Zr] - 草酸盐作为正电子发射断层显像(PET)示踪剂在炎症、肿瘤和类风湿关节炎模型中的评估
Mol Pharm. 2016 Jul 5;13(7):2571-7. doi: 10.1021/acs.molpharmaceut.6b00411. Epub 2016 Jun 20.
9
Determining organ dose conversion coefficients for external neutron irradiation by using a voxel mouse model.利用体素小鼠模型确定外中子照射的器官剂量转换系数。
J Radiat Res. 2016 Mar;57(2):182-8. doi: 10.1093/jrr/rrv078. Epub 2015 Dec 9.
10
PET with the 89Zr-labeled transforming growth factor-β antibody fresolimumab in tumor models.在肿瘤模型中进行用 89Zr 标记的转化生长因子-β 抗体 fresolimumab 的 PET 研究。
J Nucl Med. 2011 Dec;52(12):2001-8. doi: 10.2967/jnumed.111.092809. Epub 2011 Nov 9.